In humans, chronic mucocutaneous candidiasis (CMC) is characterized by infections of the skin, nail, digestive, and genital mucosae with *Candida* species, mainly *C. albicans*, a commensal of the gastrointestinal tract in healthy individuals ([@bib50]). CMC is frequent in acquired or inherited disorders involving profound T cell defects ([@bib48]; [@bib66]; [@bib37]). Human IL-17 immunity has recently been shown to be essential for mucocutaneous protection against *C. albicans* ([@bib48], [@bib50]; [@bib12]; [@bib16]; [@bib25]; [@bib36]). Indeed, patients with primary immunodeficiencies and syndromic CMC have been shown to display impaired IL-17 immunity ([@bib48]). Most patients with autosomal-dominant (AD) hyper-IgE syndrome (AD-HIES) and STAT3 deficiency ([@bib13]; [@bib39]; [@bib42]; [@bib52]; [@bib10]) and some patients with invasive fungal infection and autosomal-recessive (AR) CARD9 deficiency ([@bib19]; [@bib34]) or Mendelian susceptibility to mycobacterial diseases (MSMD) and AR IL-12p40 or IL-12Rβ1 deficiency ([@bib13], [@bib14]; [@bib46]; [@bib45]) have low proportions of IL-17A--producing T cells and CMC ([@bib12]; [@bib50]). Patients with AR autoimmune polyendocrine syndrome type 1 (APS-1) and AIRE deficiency display CMC and high levels of neutralizing autoantibodies against IL-17A, IL-17F, and/or IL-22 ([@bib6]; [@bib26]; [@bib31], [@bib32]; [@bib47]).

These findings paved the way for the discovery of the first genetic etiologies of CMC disease (CMCD), an inherited condition affecting individuals with none of the aforementioned primary immunodeficiencies ([@bib49]; [@bib7]; [@bib8], [@bib9]). AR IL-17RA deficiency, AR ACT1 deficiency, and AD IL-17F deficiency were described, each in a single kindred ([@bib49]; [@bib4]). A fourth genetic etiology of CMCD, which currently appears to be the most frequent, has also been reported: heterozygous gain-of-function (GOF) mutations of *STAT1* impairing the development of IL-17--producing T cells ([@bib38]; [@bib57]; [@bib64]; [@bib22]; [@bib59]; [@bib60]; [@bib1]; [@bib2]; [@bib54]; [@bib55]; [@bib58]; [@bib63]; [@bib68]; [@bib17]; [@bib30]; [@bib35]; [@bib41]; [@bib43]; [@bib56]; [@bib70]). We studied three unrelated patients with CMCD without mutations of *IL17F*, *IL17RA*, *ACT1*, or *STAT1*. We used a genome-wide approach based on whole-exome sequencing (WES). We found AR complete IL-17RC deficiency in all three patients.

RESULTS
=======

Clinical reports
----------------

The experiments described here were conducted in accordance with French regulations and were approved by the French Ministry of Research (IE-2010-547), the French Ethics committee (ID-RCB 2010-A00636-33), and ANSM (French National Agency for Medicines and Health Products Safety; B100712-40). Informed consent was obtained from all patients or their families, in the case of minors, in accordance with the World Medical Association, the Helsinki Declaration, and EU directives.

The index patient of kindred A (P1, kindred A.II.5, [Fig. 1 A](#fig1){ref-type="fig"}) is a 37-yr-old woman of Argentinean origin, living in Argentina, with no known parental consanguinity. The calculated homozygosity rate for P1 was 0.008 (not depicted; [@bib51]), providing further support for the notion that P1 was not from closely related parents. However, the mutation was located in a homozygous region of 7.1 Mb, which may be consistent with a cryptic consanguinity. Since the age of 4 yr, P1 has suffered from chronic intertrigo and pustules on her face, but with a normal scalp, nails, teeth, and sweating. She also developed recurrent oral (P1, kindred A.II.5, [Fig. 1 C](#fig1){ref-type="fig"}) and esophageal thrush. She had never suffered from any severe bacterial (staphylococcal, in particular), viral, or other fungal infection. P1 was treated with oral fluconazole. The response to treatment was good, with no drug resistance, but relapses occurred when treatment was stopped. Laboratory investigations showed normal immunophenotype (T, B, and NK). The T cell proliferations in response to phytohemagglutinin and antigens (tuberculin, candidin, and anatoxin) were normal. No endocrine, metabolic, or autoimmune abnormalities were reported. In particular, the patient did not display anti-DNA, antinuclear, or antithyroglobulin antibodies and had normal TSH levels. P1 had normal proportions of circulating IL-17A--, IL-17F--, IL-22--producing CD3^+^ and CD4^+^ T cells ([Fig. 2, A--C](#fig2){ref-type="fig"}) and displayed normal IL-17A production by freshly prepared leukocytes ([Fig. 3 A](#fig3){ref-type="fig"}). None of her sisters, parents, or sons had any particular relevant clinical history.

![**Three kindreds with AR IL-17RC deficiency.** (A) Pedigrees and familial segregation of the identified IL-17RC nonsense mutations. The proband is indicated in black and by an arrow. I, II, and III indicate the generations. E? indicates individuals whose genetic status could not be evaluated. (B) Schematic diagram of the IL-17RC protein, showing the signal sequence (SS), extracellular (EC), transmembrane (TM), intracellular (IC), and SEFIR (expression similar to fibroblast growth factor IL-17R) domains and the exons and amino acids affected by the mutations. (C) Recurrent thrush on tongue of P1 (kindred A.II.5) and P3 (kindred C.II.1).](JEM_20141065_Fig1){#fig1}

![**Normal ex vivo development and in vitro differentiation of IL-17-- and IL-22--producing T cells from P1.** (A--C) Each symbol represents a value from a healthy control individual (black circles), a heterozygous (WT/Q138\*) relative of P1 (black triangles), and P1 (black squares). Horizontal bars represent means. (A and B) Percentages are shown of CD3^+^/IL-17A^+^, CD3^+^/IL-17F^+^, CD3^+^/IL-22^+^, and CD3^+^/IFN-γ^+^ (A) and CD4^+^/IL-17A^+^, CD4^+^/IL-17F^+^, and CD4^+^/IL-22^+^ (B) cells, as determined by flow cytometry, among nonadherent PBMCs activated by incubation for 12 h with PMA and ionomycin. (C) Percentages are shown of IL-17A^+^, IL-22^+^, and IFN-γ^+^ T cell blasts after in vitro expansion in the presence of anti-CD3 antibody, IL-2, IL-1β, and IL-23 for 5 d, followed by 12 h of stimulation with PMA and ionomycin. The experiments were repeated at least three times.](JEM_20141065R_Fig2){#fig2}

![**Normal secretion of IL-17A and IL-22 by whole blood cells from patients.** (A--E) IL-17A (A--C) and IL-22 (D and E) secretion was determined by ELISA, in the absence of stimulation (open symbols) and after stimulation with PMA and ionomycin for 24 h (closed symbols). Horizontal bars represent medians. Each symbol represents a value from healthy control individuals (circles), heterozygous patients' relatives (triangles), or patients (squares). The experiments were repeated at least three times.](JEM_20141065_Fig3){#fig3}

The index patient of kindred B (P2, kindred B.II.1, [Fig. 1 A](#fig1){ref-type="fig"}) is a 12-yr-old boy born to Turkish parents, with no known parental consanguinity. The calculated homozygosity rate of P2 was 0.021 (not depicted), consistent with P2 originating from a family without close consanguinity. P2 has suffered from CMC since the age of 2 mo, with chronic intertrigo, aphthous stomatitis, oral thrush, and onychomycosis, but with no reported severe bacterial (staphylococcal in particular), viral, or other fungal infections. CMC was long lasting in this patient. It was treated with courses of oral and i.v. fluconazole and local nystatin, and a response to treatment was observed, but with relapse after treatment cessation. Routine laboratory investigations showed that lymphocyte counts were normal and serum IgG, IgA, IgM, and IgE levels were within the normal ranges. Thyroid function, as evaluated by determining TSH (2.4 IU/l) and T4 (1.19 ng/dl) levels, was normal. Normal levels of IL-17A and IL-22 were produced after ex vivo stimulation with PMA and ionomycin by freshly prepared leukocytes of P2 and other members of his family ([Fig. 3, B and D](#fig3){ref-type="fig"}). No endocrine, metabolic, or autoimmune abnormalities were reported. Neither the parents nor the siblings of this patient have ever suffered from severe infections.

The index patient of kindred C (P3, kindred C.II.1, [Fig. 1 A](#fig1){ref-type="fig"}) is an 8-yr-old boy from a third-degree consanguineous Turkish family. This information is consistent with the homozygosity rate of 0.039 obtained for this patient (not depicted). P3 displayed persistent oral candidiasis, with white plaques all over the buccal mucosa and dorsal surface of the tongue since early infancy (P3, kindred C.II.1, [Fig. 1 C](#fig1){ref-type="fig"}) and pustules on the skin and scalp. P3 had no history of any other significant infectious (bacterial, staphylococcal in particular, viral, or other fungal) disease or significant developmental defects, with normal hair, nails, teeth, and sweating. Leukocyte counts and absolute neutrophil and lymphocyte counts were normal. Serum IgG, IgA, and IgM levels were normal. No autoimmune antibodies, such as antinuclear, antiperoxisomal (anti-TPO and anti-TG), and antiparietal antibodies, were detected in the serum. Peripheral blood lymphocyte subsets were within the normal range. In vitro T cell proliferation tests showed that the percentages of CD3^+^CD25^+^ (66%; normal 43--97%) and CD3^+^CD69^+^ (68%; normal 45--100%) cells were within the normal ranges after stimulation with phytohemagglutinin. Normal levels of IL-17A and IL-22 secretion by freshly prepared leukocytes after ex vivo stimulation with PMA and ionomycin were observed for P3 and other members of his family ([Fig. 3, C and E](#fig3){ref-type="fig"}). No endocrine or metabolic abnormalities were found. Systemic antifungal therapy with oral fluconazole was initiated and moniliasis resolved. However, oral moniliasis recurred and persisted for some time after the cessation of treatment. Neither the parents nor the siblings of P3 had ever suffered from a severe infectious disease.

Homozygous nonsense mutations of *IL17RC*
-----------------------------------------

WES revealed the presence of different homozygous nonsense mutations of *IL17RC* in these patients. We chose to investigate these mutations further as potential disease-causing mutations because of their likely impact on IL-17 immunity. In addition, *IL17RC* displayed a very short biological distance between the known CMCD-causing genes *IL17RA* and *ACT1* (P-values of 0.0005 and 0.0007, respectively), making it a very likely novel candidate gene for CMCD ([@bib28]). P1 was found to be homozygous for the *c.412C\>T* nonsense mutation in exon 3 of the *IL17RC* gene. This mutation replaces the glutamine codon at position 138 with a premature stop codon (Q138\*; [Fig. 1 B](#fig1){ref-type="fig"}). The healthy parents, tested siblings, and children of P1 were all heterozygous (WT/Q138\*) for the mutant allele, consistent with AR inheritance for this trait ([Fig. 1 A](#fig1){ref-type="fig"}). P2 was found to be homozygous for the *c.1126C\>T* nonsense mutation in exon 11 of the *IL17RC* gene. This mutation replaces the arginine codon in position 376 with a premature stop codon (R376\*; [Fig. 1 B](#fig1){ref-type="fig"}). The parents and sister of P2 are healthy and heterozygous for the mutant allele, consistent with AR inheritance ([Fig. 1 A](#fig1){ref-type="fig"}). P3 was found to be homozygous for the *c.1132C\>T* nonsense mutation in exon 11 of the *IL17RC* gene, replacing the arginine codon in position 378 with a premature stop codon (R378\*; [Fig. 1 B](#fig1){ref-type="fig"}). The parents and sister of P3 are healthy and heterozygous for the mutant allele, consistent with AR inheritance ([Fig. 1 A](#fig1){ref-type="fig"}). The mutant allele (Q138\*) from P1 was not found in any of the various public databases (Human Gene Mutation Database, Ensembl, NHLBI GO Exome Sequencing Project \[ESP\], 1000 Genomes Project, and the Exome Aggregation Consortium \[ExAC\]) or in our in-house WES database (∼1,800 exomes), ruling out the possibility of an irrelevant polymorphism and suggesting that this mutation may define a rare AR CMCD-causing allele. The R376\* mutant allele, found in P2, has been reported in the ExAC database, only at the heterozygous state, in 5 out of 59,269 individuals. The R378\* mutant allele found in P3 has been reported previously (dbSNP accession no. rs143600903), but with a low frequency (0.057%); only one European from a population of 59,318 individuals has been found to be homozygous for this variant, consistent with the notion that this mutation may define a rare AR CMCD-causing allele. The three premature stop codons are located upstream from the segment encoding the transmembrane domain of IL-17RC ([Fig. 1 B](#fig1){ref-type="fig"}). No rare coding mutations were found in *STAT1*, *IL17RA*, *IL17A*, *IL17F*, *ACT1*, *IL22*, or *IL22RA1* by WES in the three patients.

Impaired production of *IL17RC* mRNA and protein
------------------------------------------------

We used RT-PCR or TaqMan assays to determine the levels of full-length *IL17RC* mRNA, which we found to be lower in fibroblasts from the patients than in cells from healthy controls ([Fig. 4, A and B](#fig4){ref-type="fig"}). However, no band of the correct size corresponding to IL-17RC could be detected by Western blot in control fibroblasts without transfection. Therefore, the patients' fibroblasts were then transfected with various expression vectors: an empty vector or vectors encoding the WT or any of the three mutant alleles (Q138\*, R376\*, or R378\*). In this overexpression system, the *IL17RC* mRNAs generated by transcription from the WT allele or the three mutant alleles were detected equally well by qPCR ([Fig. 4 C](#fig4){ref-type="fig"}). A product of ∼85 kD, corresponding to isoform 1, was detected in cells transfected with the WT *IL17RC* allele, whereas no product of this molecular mass was detected in fibroblasts transfected with any of the three mutant *IL17RC* alleles ([Fig. 4 D](#fig4){ref-type="fig"}). No product with a lower molecular mass was detected in cells transfected with the Q138\* IL-17RC--encoding construct, with an anti--IL-17RC antibody directed against the epitope covering amino acids 113--258. A product with a lower molecular mass (∼40 kD), corresponding to a C-terminally truncated protein, was detected in cells transfected with the constructs encoding R376\* or R378\* IL-17RC. A product of ∼80 kD was detected in cells transfected with the WT allele and a product of ∼35 kD was detected in cells transfected with the R376\* or R378\* allele. These products were probably the result of posttranscriptional modifications. In addition, HEK-293T cells transfected with various constructs encoding IL-17RC WT, Q138\*, R376\*, or R378\* displayed a strong membrane expression, as detected by total internal reflection fluorescence (TIRF) imaging, only when transfected with the WT allele but none of the mutants alleles ([Fig. 5 A](#fig5){ref-type="fig"}). The absence of IL-17RC had no impact on the expression of IL-17RA, which was found to be expressed to similar levels on the fibroblasts of patients and controls ([Fig. 5 B](#fig5){ref-type="fig"}).

![**Expression of IL-17RC in fibroblasts from controls and patients.** (A and B) Amounts of *IL17RC* cDNA generated from SV40-immortalized fibroblasts from two controls and two patients (P1 and P2), as determined by full-length RT-PCR (A) and TaqMan assays (B). (C) Amounts of *IL17RC* cDNA obtained from the SV40 fibroblasts of P1 and P2 either left untransfected (NT) or transfected with pUNO1, either empty (MCS) or encoding the WT, Q138\*, R376\*, or R378\* IL-17RC. Results are also shown for the SV40 fibroblasts of two controls tested in parallel (C1 and C2). Means ± SD (error bars) of three independent experiments, as detected by quantitative PCR, are shown. β-ACTIN and GUS were used as endogenous controls. The experiments were repeated at least three times. (D) IL-17RC expression in P1's and P2's SV40 fibroblasts transfected with WT or mutant *IL17RC* alleles, as assessed by Western blotting. IL-17RC protein levels in SV40 fibroblasts from P1 and P2 transfected with the empty pUNO1mcs plasmid (mock) or the pUNO1 plasmid, encoding the WT or one of the three mutant (Q138\*, R376\*, or R378\*) IL-17RC proteins, as determined by Western blotting with an anti--IL-17RC antibody (directed against amino acids 113--258). The anti-GAPDH antibody was used as a control for protein loading. These experiments were repeated at least three times.](JEM_20141065R_Fig4){#fig4}

![**Expression of WT, mutant IL-17RC, and IL-17RA at the cell surface.** (A) IL-17RC expression in HEK-293T cells transfected with V5 tag plasmid encoding IL-17RC WT or mutant alleles, as assessed by TIRF imaging. HEK-293T cells were transfect with V5 tag--*IL17RC*-pcDNA 3.1 encoding WT or mutant (Q138\*, R376\*, or R378\*) IL-17RC. The "Epi" was assessed by epifluorescence illumination, and the "TIRF" was detected by TIRF microscopy. DAPI binds double-stranded DNA, and phalloidin binds F-actin. The "pseudocolor" scales were used to indicate the intensity staining in TIRF. For each setting condition, 20 cells have been analyzed from cumulating three independent experiments. Bars, 5 µm. (B) IL-17RA expression on SV40-immortalized fibroblasts from a control, P1 (Q138\*/Q138\*), P2 (R376\*/R376\*), and an IL-17RA--deficient patient (Q284\*/Q284\*), as assessed by flow cytometry. Isotype control, gray dotted lines; IL-17RA antibody, black lines. The experiments were repeated at least three times.](JEM_20141065R_Fig5){#fig5}

Impaired responses to IL-17A and IL-17F, but normal responses to IL-17E/IL-25
-----------------------------------------------------------------------------

We investigated whether the three *IL17RC* mutations identified had any functional consequences in terms of the response to IL-17 cytokines by testing the responses of the patients' fibroblasts to various concentrations (10 and 100 ng/ml) of recombinant IL-17A and IL-17F homodimers and IL-17A/F heterodimers. Unlike fibroblasts from healthy controls, the patients' fibroblasts did not respond to any of the three IL-17 dimers, whatever the concentration of cytokine used. These results were similar to those obtained for the IL-17RA--deficient patient carrying the homozygous Q284\* mutation tested in parallel, in terms of IL-6 and GRO-α (growth-regulated oncogene-α) induction, as assessed by ELISA ([Fig. 6, A and B](#fig6){ref-type="fig"}). In contrast, the responses of the patients' fibroblasts to IL-1β stimulation were within the same range as the controls. Transfection of the patients' fibroblasts with a WT *IL17RC* construct, but not with an empty vector or with any of the three mutant constructs, restored the response to IL-17 cytokines in the patients' fibroblasts ([Fig. 7, A and B](#fig7){ref-type="fig"}). In contrast, PBMCs from P2 and P3 stimulated with IL-17E/IL-25 in the presence of IL-2 produced IL-5 to levels in the control range, in contrast to what was observed for PBMCs from an IL-17RA--deficient patient. Thus, IL-17E/IL-25 signaling in humans is dependent on IL-17RA but not IL-17RC ([Fig. 8](#fig8){ref-type="fig"}). The three patients described here display a complete form of AR IL-17RC deficiency, with a lack of cellular responses to IL-17A and IL-17F homo- and heterodimers but normal responses to IL-17E/IL-25.

![**Responses of P1's and P2's fibroblasts to IL-17 cytokines.** (A and B) IL-6 (A) and GRO-α (B) production by SV40-immortalized fibroblasts from controls, P1 (IL-17RC Q138\*/Q138\*), P2 (IL-17RC Q376\*/Q376\*), and an IL-17RA--deficient patient (IL-17RA Q284\*/Q284\*), after 24 h of stimulation with IL-17A (10 and 100 ng/ml), IL-17F (10 and 100 ng/ml), and IL-17A/IL-17F (10 and 100 ng/ml), as determined by ELISA on supernatants. Means ± SD (error bars) of three independent experiments are shown. Statistical analyses were performed by the nonparametric statistical test (Mann--Whitney test), comparing NS (nonstimulated) and activated samples (\*, P \< 0.05; \*\*, P \< 0.01). The experiments were repeated at least three times.](JEM_20141065R_Fig6){#fig6}

![**Production of IL-6 and GRO-α by the patients' fibroblasts in responses to IL-17 cytokines, after transfection with the WT or mutant *IL17RC* alleles.** (A and B) IL-6 and GRO-α production by SV40-immortalized fibroblasts from a control, P1, P2, and an IL-17RA--deficient patient transfected with an empty vector (mock) or an IL-17RC vector encoding the WT or each one of the mutant (Q138\*, R376\*, or R378\*) proteins, after 24 h of stimulation with 100 ng/ml IL-17A, as determined by ELISA on supernatants. NS, nonstimulated; NT, not transfected. Means ± SD (error bars) of three independent experiments are shown. Statistical analyses were performed by the nonparametric statistical test (Mann--Whitney test; \*\*, P \< 0.01). The experiments were repeated at least three times.](JEM_20141065_Fig7){#fig7}

![**IL-17E/IL-25 response of the patients' T cells.** PBMCs from 14 controls, P2 and P3, 11 healthy heterozygous relatives, and an IL-17RA--deficient patient were cultured in thymic stromal lymphopoietin for 24 h, harvested, and restimulated with IL-2 and IL-17E/IL-25 for an additional 72 h. IL-5 concentrations in the culture supernatants were determined by ELISA. Errors bars represent SEM. Statistical analyses were performed by the nonparametric statistical test (Mann--Whitney test; \*\*, P \< 0.01). The experiments were repeated at least three times.](JEM_20141065_Fig8){#fig8}

Normal cellular responses to fungal compounds
---------------------------------------------

Finally, we investigated IL-6, IFN-γ, and IL-17A production by P2's whole blood upon 48 h of stimulation with fungal compounds (Curdlan, heat-killed *C. albicans*, *Saccharomyces cerevisiae*, and *Exophiala dermatitidis*), as well as heat-killed *Staphylococcus aureus*, vesicular stomatitis virus (VSV), bacillus Calmette--Guérin (BCG), and PMA/ionomycin. The levels of all three cytokines produced were comparable with those obtained after whole blood stimulation of a local or a travel control ([Fig. 9, A--C](#fig9){ref-type="fig"}). Similarly, monocyte-derived DCs (MDDCs) from P2, P3, and their relatives, activated with various fungal compounds (including zymosan, heat-killed *S. cerevisiae*, *C. albicans*, *E. dermatitidis*, and Curdlan), as well as VSV, BCG, or LPS, produced levels of TNF comparable with the healthy controls tested in the same conditions ([Fig. 10, A and B](#fig10){ref-type="fig"}). Altogether, these results suggest that IL-17RC deficiency does not impair the whole blood or MDDC response to fungal compounds, at least for the cytokines measured, including IL-17A. Altogether, these data suggest that the patients' defective IL-17RC--dependent responsive pathway is primarily responsible for CMC, as it does not affect the production of IL-17A and other cytokines by leukocytes and MDDCs in response to stimulation by *C. albicans*.

![**Normal IL-6, IFN-γ, and IL-17A production by P2's whole blood upon 48 h of stimulation with fungal compounds.** (A--C) Whole blood from a local control (white bars), a travel control (gray bars), and P2 (black bars) were stimulated with fungal compounds (Curdlan, heat-killed *C. albicans*, *S. cerevisiae*, *E. dermatitidis*: a black yeast), as well as heat-killed *S. aureus*, VSV, BCG, or PMA/ionomycin for 48 h. IL-6 (A), IFN-γ (B), and IL-17A (C) were measured by ELISA. The experiments were repeated two times.](JEM_20141065R_Fig9){#fig9}

![**Normal TNF production by P2's and P3′s MDDCs upon 48 h of stimulation with fungal compounds.** (A and B) MDDCs from four healthy control individuals (white bars), four heterozygous patients' relatives (gray bars), and P2 or P3 (black bars) were stimulated with fungal compounds (zymosan, heat-killed *S. cerevisiae* \[HKSC\], *C. albicans* \[HKCA and SC5314\], *E. dermatitidis*, and Curdlan), as well as with VSV, BCG, or LPS for 48 h. TNF was measured by ELISA. Error bars represent SEM. The experiments were repeated two times.](JEM_20141065R_Fig10){#fig10}

DISCUSSION
==========

The molecular and cellular basis of human CMC, which is common in patients with various conditions, was eventually deciphered thanks to the study of rare patients with CMCD, in whom CMC appears as the main clinical manifestation, without other severe infectious or autoimmune clinical signs ([@bib48], [@bib50]). Four genetic etiologies of CMCD have been described. AR IL-17RA and AD IL-17F deficiencies were the first two genetic etiologies to be discovered, through a candidate gene approach ([@bib49]). IL-17RA deficiency is complete, abolishing cellular responses to IL-17A and IL-17F homo- and heterodimers and to IL-17E/IL-25 ([@bib49]; [@bib4]). In contrast, IL-17F deficiency is partial, with impairment but not total abolition of the activity of homo- and heterodimers containing the mutant IL-17F ([@bib49]). Genome-wide approaches subsequently led to the discovery of heterozygous GOF mutations of *STAT1* as the third and, to date, by far the most frequent genetic etiology of CMCD ([@bib5]). Stronger STAT1-dependent cellular responses to the STAT1-dependent IL-17 inhibitors IFN-α/β, IFN-γ, and IL-27 and to the STAT3-dependent IL-17 inducers IL-6, IL-21, and IL-23 may account for the poor development of IL-17--producing T cells observed in patients bearing such mutations ([@bib38]). An AR deficiency of the adaptor molecule ACT1 was recently found in two siblings and identified as the fourth genetic etiology of CMCD ([@bib4]). The patients' fibroblasts failed to respond to IL-17A and IL-17F, and their T cells did not respond to IL-17E/IL-25 ([@bib4]). We describe here AR complete IL-17RC deficiency, a new genetic etiology of CMCD, in three unrelated sporadic cases, further documenting the crucial role of human IL-17 immunity in mucocutaneous protection against *C. albicans*.

IL-17RC, one of the five members of the IL-17 receptor family, is a key component of the IL-17A and IL-17F receptor, as it forms a heterotrimeric receptor complex together with IL-17RA ([@bib44]; [@bib61]; [@bib67]; [@bib15]; [@bib18]; [@bib20]; [@bib21]). Mouse IL-17RC (mIL-17RC), like mIL-17RA ([@bib40]), is essential for signaling downstream from mIL-17A, mIL-17F, and mIL-17A/F, both in vitro and in vivo ([@bib20]; [@bib23]), as in humans ([@bib49]). However, mouse and human IL-17RC and IL-17RA have different binding affinities for IL-17A and IL-17F ([@bib33]). In humans, IL-17RA binds preferentially to IL-17A and has a lower affinity for IL-17F ([@bib69]). In contrast, IL-17RC binds IL-17A and IL-17F with a similar affinity ([@bib33]; [@bib20]). The opposite situation occurs in mice: mIL-17RA binds mIL-17A and mIL-17F with equal affinities, but mIL-17RC binds preferentially to mIL-17F ([@bib33]; [@bib20]). Moreover, after its heterodimerization with mIL-17RB, mIL-17RA has been shown to be involved in the IL-17E/IL-25 signaling pathway in mice ([@bib53]; [@bib23]). Consistently, IL-17RA--deficient patients do not respond to IL-17E/IL-25 ([@bib4]). In contrast, mIL-17RC has not been shown to be part of another receptor ([@bib20]), at least for mIL-17E/IL-25 signaling ([@bib24]). We show here that IL-17E/IL-25 signaling is normal in humans with IL-17RC deficiency. Our findings demonstrate that human IL-17RC deficiency prevents cellular responses to IL-17A and IL-17F dimers but not to IL-17E/IL-25.

The infectious phenotype of the IL-17RC--deficient patients is consistent with that of mIL-17RC--deficient mice ([@bib20]; [@bib23]). IL-17RC--deficient mice displayed a large fungal burden in the oral cavity in a model of oropharyngeal candidiasis (OPC; [@bib20]; [@bib62]). Likewise, the IL-17RC--deficient patients displayed recurrent or persistent oral candidiasis with or without skin and/or nail involvement from early infancy onward. This phenotype, restricted to isolated CMC, is similar to that of patients with AD IL-17F, AR IL-17RA, and AR ACT1 deficiencies ([@bib49]; [@bib4]). However, patients with AR IL-17RA and AR ACT1 deficiencies also display peripheral staphylococcal infections, such as dermatitis ([@bib49]) and blepharitis ([@bib4]). It is tempting to speculate that these infections might result, at least in part, from impaired IL-17E/IL-25 responses, which are normal in IL-17F-- and IL-17RC--deficient patients. Susceptibility to cutaneous staphylococcal disease has been observed in mIL-17RA--deficient mice ([@bib3]; [@bib11]; [@bib65]; [@bib2]). Spontaneous occurrence of peripheral *S. aureus* infection was also observed in double mIL-17A/mIL-17F but not in single mIL-17A or mIL-17F knockout mice ([@bib27]). mIL-17RC-- and mACT1-deficient mice have yet to be tested. Finally, patients with AD STAT1 GOF have a broader infectious phenotype, which is probably the result of the broader cellular impact of the mutations (unpublished data). Overall, our data demonstrate that human IL-17 signaling via IL-17RC is essential for mucocutaneous immunity to *C. albicans*, but suggest that this signaling is redundant for immunity to most other common pathogens, even possibly including *S. aureus*. Moreover, human IL-17RC is not required for cellular responses to IL-17E/IL-25.

MATERIALS AND METHODS
=====================

### Molecular genetics.

Genomic DNA was isolated from whole blood by a phenol/chloroform extraction method. *IL17RC* cDNA was amplified with specific primers. PCR products were analyzed by electrophoresis in 1% agarose gels, sequenced with the Big Dye Terminator cycle sequencing kit (Applied Biosystems), and analyzed on an ABI Prism 3700 apparatus (Applied Biosystems).

### Massively parallel sequencing.

3 µg genomic DNA was extracted from the peripheral blood cells of the patients and sheared with an S2 Ultrasonicator (Covaris). An adaptor-ligated library was prepared with the Paired-End Sample Prep kit V1 (Illumina). Exome capture was performed with the SureSelect Human All Exon kit (Agilent Technologies). Single-end sequencing was performed on a Genome Analyzer IIx (Illumina), generating 72 base reads.

### Cell purification and culture.

Human PBMCs were isolated from whole blood by Ficoll-Hypaque density gradient centrifugation (GE Healthcare). Primary human fibroblasts, obtained from skin biopsy specimens, were immortalized with SV40T antigen (SV40 fibroblasts) and cultured in DMEM (Gibco, Invitrogen) supplemented with 10% FBS (Gibco, Invitrogen). HEK-293T cells were cultured in DMEM supplemented with 10% FBS. All cells were grown at 37°C, under an atmosphere containing 5% CO~2~.

### RT-PCR for full-length IL-17RC and TaqMan probe detection.

Total RNA was extracted with the RNeasy Mini kit (QIAGEN) and reversed-transcribed to generate cDNA with the High-Capacity cDNA Reverse Transcription kit (Invitrogen). Platinum High-Fidelity *Taq* DNA Polymerase (Invitrogen) was then used to amplify the full-length *IL17RC* cDNA.

The following primers were used: F, 5′-CTGAAGAGGGATTCCAGCCC-3′ and R, 5′-GTAGAAAAACAGCGTCTGCC-3′. TaqMan probes for IL-17RC (Invitrogen) were used to detect mRNA, and the results were normalized against those for GUS (Human GUSB Endogenous Control VIC/MGB Probe; Primer Limited, Invitrogen).

### IL-17RC detection by Western blotting.

Total protein extracts were prepared from SV40 fibroblasts or HEK-293T cells 48 h after transfection. The proteins were separated by electrophoresis. The bands were electroblotted onto a membrane, which was then probed with an antibody against IL-17RC (Sigma-Aldrich) or GAPDH (Santa Cruz Biotechnology, Inc.).

### Fibroblast activation.

SV40-transformed fibroblasts were plated in 48-well plates at a density of 50,000 cells/well in 0.5 ml DMEM/10% FBS per well. The cells were incubated for 24 h and were then left unstimulated or were stimulated for 24 h with various amounts of IL-17 cytokines, recombinant human IL-17A, IL-17F, IL-17A/F, and IL-1β (from R&D Systems). 24 h later, supernatants were collected and IL-6 (Sanquin or R&D Systems) and GRO-α (R&D Systems) levels were assessed with ELISA kits, according to the manufacturer's instructions.

### PBMC culture.

Frozen PBMCs were cultured in the presence of 100 ng/ml thymic stromal lymphopoietin (R&D Systems) in X-VIVO 15 (Lonza) plus 5% human AB serum (Lonza), as previously described ([@bib53]). PBMCs were collected, washed, and resuspended at a density of 4 × 10^6^ cells/well in 48-well plates, in a final volume of 0.5 ml/well, in the presence of 10 ng/ml recombinant human IL-2 (R&D Systems) and 10 ng/ml recombinant human IL-17E/IL-25 (R&D Systems). After 3 d, the amount of IL-5 secreted into the medium was determined with ELISA kits (R&D Systems).

### PBMC activation.

The levels of IL-17A-- and IL-22--producing T cells were evaluated by intracellular staining or by ELISA, as previously described ([@bib13]). In brief, PBMCs were purified by centrifugation on a gradient (Ficoll-Paque PLUS; GE Healthcare) and resuspended in RPMI supplemented with 10% FBS (RPMI/10% FBS; Invitrogen). Adherent monocytes were removed from the PBMC preparation by incubation for 2 h at 37°C, under an atmosphere containing 5% CO~2~. For the ex vivo evaluation of IL-17-- and IL-22--producing T cells by flow cytometry, we resuspended 5 × 10^6^ nonadherent cells in 5 ml RPMI/10% FBS in 25-cm^2^ flasks and stimulated them by incubation with 40 ng/ml PMA (Sigma-Aldrich) and 10^−5^ M ionomycin (Sigma-Aldrich) in the presence of a secretion inhibitor (1 µl/ml GolgiPlug; BD) for 12 h. For the evaluation of the IL-17-- and IL-22--producing T cell blasts after in vitro differentiation, the nonadherent PBMCs were dispensed into 24-well plates at a density of 2.5 × 10^6^ cells/ml in RPMI/10% FBS and activated by incubation with 2 µg/ml of an antibody directed against CD3 (Orthoclone OKT3; Janssen-Cilag) either alone or together with 20 ng/ml IL-23 (R&D Systems), 50 ng/ml IL-6 (R&D Systems), 10 ng/ml IL-1β (R&D Systems), or combinations of these three cytokines. After incubation for 3 d, the cells were restimulated in the same activation conditions, except that the anti-CD3 antibody was replaced with 40 IU/ml IL-2 (Proleukin i.v.; Chiron). We added 1 ml of the appropriate medium, resuspended the cells by gentle pipetting, and then split the cell suspension from each well into two. Flow cytometry was performed on one of the duplicated wells 2 d later, after stimulation by incubation for 12 h with 40 ng/ml PMA and 10^−5^ M ionomycin in the presence of 1 µl/ml GolgiPlug. Cells were washed in cold PBS, and surface labeling was achieved by incubating the cells with VioBlue-anti--human CD3 (Miltenyi Biotec) or FITC-anti--human CD4 (BD) antibody in 2% FBS in PBS for 20 min on ice. The cells were then washed twice with 2% FBS in cold PBS, fixed by incubation with 100 µl Cytofix for 30 min on ice, and washed twice with Cytoperm (Cytofix/Cytoperm Plus fixation/permeabilization kit; BD). The cells were then incubated for 1 h on ice with Alexa Fluor 488--conjugated anti--human IL-17A (eBioscience), IL-17F PE-conjugated anti--human IL-22 (R&D Systems), or PE-conjugated anti--human IFN-γ (R&D Systems) antibodies, washed twice with Cytoperm, and analyzed with a FACSCanto II system (BD).The contents of the other duplicated well were split into two, with one half left unstimulated and the other stimulated by incubation with 40 ng/ml PMA and 10^−5^ M ionomycin for another 2 d. Supernatants were collected after 48 h of incubation for ELISA.

### Flow cytometry.

SV40 fibroblasts were plated in 24-well plates at a density of 50,000 cells/well, in 0.5 ml of 10% FBS in DMEM per well. The plates were incubated for 24 h. The cells were then subjected to flow cytometry. SV40-transformed fibroblasts or PBMCs were labeled with PE-mouse IgG1 (eBioscience), APC-mouse IgG1 (eBioscience), Alexa Fluor 647 mouse IgG1, κ isotype ctrl (FC) antibody (Sony Biotechnology, Inc.), VioGreen-mouse IgG2a (Miltenyi Biotec), VioBlue-mouse IgG2a (Miltenyi Biotec), FITC-mouse IgG1 (BD), FITC-mouse IgG2b (BD), and PE-mouse IgG1 (BD) antibodies or Alexa Fluor 647--mouse IgG1 (eBioscience) isotype antibodies as a control. PE-anti--human IL-17RA (clone J10MBS; eBioscience), APC-anti--human IL-17RA (clone 424LTS; eBioscience), Alexa Fluor 647 anti--human CD217 (IL-17RA) antibody (Sony Biotechnology, Inc.), VioGreen-anti--human CD14 (Miltenyi Biotec), VioBlue-anti--human CD3 (Miltenyi Biotec), FITC-anti--human CD4 (BD), FITC-anti--human CD8 (BD), FITC-anti--human CD14 (BD), FITC-anti--human CD19 (BD), and FITC-anti--human CD56 (BD) specific antibodies were used according to the manufacturers' instructions, with the results analyzed by flow cytometry on a FACSCanto II system.

### The TIRF assay.

The TIRF assay was performed on the transfected HEK-293T cells as described in "Cell purification and culture." V5 tag--IL-17RC WT and mutant (Q138\*, R376\*, and R378\*) vectors were constructed at the N terminus by the pcDNA3.1 Directional TOPO Expression kit (Life Technologies). After being fixed in 3.7% paraformaldehyde, the cells coated glass coverslips and were incubated with anti-V5 antibody (Life Technologies) and Phalloidin (Life Technologies) for 3 h at room temperature. After being washed, the glass coverslips were incubated with anti--mouse Alexa Fluor 488 (Life Technologies) for 1 h at room temperature and then stained with DAPI (Sigma-Aldrich). Fluorescence data were acquired with the Eclipse Ti-E TIRF imaging system (Nikon). Images were recorded with the QuanTEM 512 SC camera (Roper Scientific) and acquired with NIS-Elements AR software (version 3.1; Nikon). Image sets were processed with ImageJ version 1.43 software (National Institutes of Health).

### Cell complementation.

IL-17RC--deficient and IL-17RA--deficient SV40 fibroblasts were transfected with empty pUNO1-msc vectors, pUNO1--hIL-17RCa encoding WT human IL-17RC, or pUNO1--hIL-17RA encoding WT human IL-17RA (InvivoGen) with the Lipofectamine LTX transfection kit (Invitrogen), used according to the manufacturer's instructions. The cells were incubated for 24 h and then stimulated with IL-17A, IL-17F, and IL-17A/F (R&D Systems) at a concentration of 10 or 100 ng/ml. After 24 h, supernatants were harvested for the assessment of IL-6 and Gro-α levels by ELISA, and cells were collected for the evaluation of IL-17RC expression by FACS analysis.

### Statistical analysis.

Data were analyzed with the nonparametric statistical test (Mann--Whitney test) with Prism software (GraphPad Software), and P \< 0.05 or P \< 0.01 was considered statistically significant. Biological proximities between *IL17RC* and the known CMC-causing genes *IL17RA* and *ACT1* were estimated using the human gene connectome method and its online server ([@bib29]).

### Healthy controls.

The healthy controls were volunteer blood donors originating from the European Union, Turkey, or Argentina.
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